GODAVARIB

What Godavari Biorefineries promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q4 FY26

what the last two calls moved 8 tracked 1 delivered 0 missed 7 open
  • R&D Milestone delivered said Q4 FY25 Promised: Safety trial is expected to be complete in Q2 FY26. Q4 FY26: Remains achieved. Company confirms safety trials are complete and is now preparing application to CDSCO for efficacy trials.
  • Capacity Commissioning Timeline delayed said Q3 FY25 Promised: Targeting for commissioning from Q4 of the coming financial year which is H2 FY26. Q4 FY26: Further delayed. Commissioning trials now expected in June 2026 (Q1 FY27), pushed from the previous target of March/April 2026.
  • EBITDA Growth on track said Q4 FY25 Promised: Targeting an increase in EBITDA by about 3x of FY25 numbers by FY29 (approx INR 360 crores). Q4 FY26: FY26 EBITDA grew 15.8% YoY to INR 139 crores, a step towards the FY29 goal of ~INR 360 crores. Growth drivers (chemicals, new distillery) are progressing.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 8 tracked commitments for Godavari Biorefineries — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens